Background {#Sec1}
==========

Perioperative hyperglycemia is associated with poor outcomes including surgical site infections, possibly related to impaired phagocytic function, \[[@CR1]\] and increased length of hospital stay. The evidence supporting strict control in critically ill patients was first published almost 16 years ago, \[[@CR2]\] but the findings were not confirmed within other studies, the results of which suggest a lower risk of death with conventional control rather than strict control \[[@CR3], [@CR4]\]. During cardiac surgery \[[@CR5]\] there is a significant reduction in pulmonary, renal complications and death with blood glucose (BG) \< 200 mg/dL although there is no improved outcome with strict glucose control (target BG was between 80 and 100 mg/dl) \[[@CR6]\]. Despite increasing trends towards treating high BG values in the perioperative setting the degree of control remains controversial \[[@CR7]\].

Patients presenting for liver transplantation frequently display insulin resistance, termed hepatogenous diabetes \[[@CR8], [@CR9]\]. In addition, surgical stress, steroids, transfusion and the onset of gluconeogenesis after reperfusion of the new graft result in glucose instability. A retrospective study revealed better outcomes for patients undergoing orthotopic liver transplant (OLT) when the mean intraoperative BG was kept below 150 mg/dL \[[@CR10]\] but prospective studies evaluating BG management during OLT are lacking. Here, we conducted a prospective randomized trial comparing strict versus conventional glucose control for patients undergoing OLT at a single academic medical center. We hypothesized that strict intra-operative blood glucose control improves one-year survival and decreases surgical complications, including infections, following OLT.

Methods {#Sec2}
=======

Study design and patient selection {#Sec3}
----------------------------------

Following approval from University of Michigan Medical School Institutional Review Board, Ann Arbor, Michigan (HUM 0016106/HUM 00139554) and written informed consent, adult patients undergoing OLT were randomized to either strict or conventional glycemic control ([ClinicalTrials.gov](http://clinicaltrials.gov) ID: NCT00780026). Block randomization was performed by the study coordinator for diabetic and nondiabetic patients. Subjects were blinded to randomization group but not the clinicians. Post-operative glucose control was directed by the same standard sliding scale protocol used by the intensive care unit for both study groups. This clinical trial is in compliance with CONSORT (Consolidated Standards of Reporting Trials) statement \[[@CR11]\].

Adult patients ≥18 years' old who were undergoing liver transplantation were approached for study participation. The exclusion criteria included: Multi-organ transplant recipients, patients receiving an ABO incompatible liver, HIV infected patients, recipients of an organ from a HIV positive donor, patients who were unable to give informed consent, use of investigational drugs at the time of enrollment or within 30 days or 5 half-lives of enrollment, patients transplanted for hepatocellular carcinoma exceeding 3 nodules or with nodule diameter larger than 5 cm, and a history of malignancy of any organ system treated or untreated within the past 5 years, with the exception of localized basal cell carcinoma of the skin.

All patients received standard induction of anesthesia using fentanyl (1--2 mcg/kg), propofol (0.5--2 mg/kg), and muscle relaxation using either succinylcholine and/or cisatracurium as deemed appropriate by the anesthesiologist. Anesthesia was maintained with volatile agent. Infusions of cisatracurium for muscle relaxation and fentanyl for analgesia were continued throughout surgery. Methylprednisolone 500 mg was given as a standard immunosuppression to all patients. The use of inotropes and vasopressors were at the discretion of the anesthesiologist and in response to the patient's hemodynamic status. Invasive hemodynamic monitoring included arterial and central venous access for all patients. Transesophageal echocardiography was placed unless contra-indicated by esophageal pathology or difficulty of placement. Pulmonary artery catheters were placed when thought necessary by the anesthesiologist.

Intraoperative blood glucose management {#Sec4}
---------------------------------------

A dedicated peripheral IV was used for all intravenous insulin administration and infusion tubing was flushed with 20 mls of insulin solution before the tubing was connected directly to the cannula without a carrier. Treatment algorithms were dictated by randomization. BG analysis were performed on arterial blood samples (Gem Premier 3000 ABG analyzer, Instrumentation Laboratory, USA) and repeated every 30 min.

The BG target for intervention in the strict glycemic control group was between 80 and 120 mg/dL. The trigger for treatment was a single BG \> 130 or two BG \> 120 when checked 30 min apart. Insulin treatment was by intravenous infusion, the rate of which was varied resultant upon glucose level and response to therapy according to the protocol (Table [1](#Tab1){ref-type="table"}). Table 1Intraoperative glucose management protocol for standard glycemic controlInsulin Infusion InitiationBG (mg/dL)Bolus Regular Insulin Units IV pushInitial Insulin Drip Rate Units/hr\< 18000181--20002201--30033\> 30044Insulin Infusion titrationBG mg/dLInsulin Infusion (units per hour) Regular Insulin at Concentration of 1 unit/dL\<  70Hold infusion, give 25 ml of 50% dextrose IV bolus (1/2 vial). Re-check BG every 15 min until BG \> 70 mg/dL, then every 30 min. When BG \> 120 mg/dL restart infusion at 50% of last rate.70--79Hold infusion: When BG \> 120 mg/dL restart infusion at 50% of last rate80--99Decrease infusion by 50% of last rate100--200Continue current infusion rate unless BG reduced by \> 50 mg/dl since last test, then decrease rate by 1unit/hour.201--250Increase 1 unit/hr unless BG reduced by \> 50 mg/dl since last test, then decrease rate by 1unit/hour.251--300Increase by 2 units/hour unless BG reduced by \> 50 mg/dl since last test, then decrease rate by 1unit/hour.301--400Bolus 4 units regular insulin IV; increase infusion by 3 units/hour.\>  400Bolus 5 units regular insulin IV; increase infusion by 4 units/hourTarget: 180--200 mg/dLTrigger: One blood glucose \> 200 or two blood glucoses \> 180 when checked 30 min apartHypoglycemia protocol (If blood glucose \< 70 mg/dL): Hold infusion, give 25 ml of 50% dextrose IV bolus (1/2 vial) and start 50mls/hr. 10% glucose. Re-check BG every 15 min until BG \> 70 mg/dL, then every 30 min

The BG target for intervention in the conventional control group was 180-200 mg/dL. The trigger for treatment included one value \> 200 or two values \> 180 mg/dL when checked 30 min apart. Insulin infusion rate was titrated as per protocol. In addition to the continuous intravenous infusion, insulin by intravenous bolus was given if BG \> 200 mg/dL (Table [2](#Tab2){ref-type="table"}). Table 2Intraoperative glucose management protocol for strict glycemic controlInsulin Infusion ProtocolColumn 1†Column 2‡Column 3§Serum Glucose Level, mg/dLInsulin Infusion Rate, U/hSerum Glucose Level, m/dLInsulin Infusion Rate, U/hSerum Glucose Level, mg/dLInsulin Infusion Rate, U/h\> 40018\> 40025\> 40030351--40016351--40022351--40027301--35014301--35020301--35024251--30012251--30018251--30021201--25010201--25015201--25018176--2008176--20012176--20015151--1756151--1759151--17512121--1504121--1507121--1509101--1202101--1204101--120680--100180--100280--1003\< 80Off\< 80Off\< 80Off^**1**^When glucose level is \< 80 mg/dL, stop insulin infusion and initiate 50 mL/h of 10% dextrose infusion. Check glucose every 30 min until glucose level is ≥80 mg/dL - Discontinue 10% dextrose infusion. Resume insulin infusion, always in column 1. If glucose level is \< 70 mg/dL, initiate treatment of hypoglycemia protocol. Restart insulin infusion in column 1 when glucose level ≥ 80 mg/dL† Start in this column; restart in this column when insulin infusion has to be discontinued for glucose level \< 80 mg/dL‡ Patient has not reached glucose level range of 80--110 mg/dL within 2 h of using column 1 and glucose level has decreased by \< 50 mg/dL over preceding 1 h§ Patient had not reached glucose level range of 80--110 mg/dL within 2 h of using column 2 and glucose level has decreased by \< 50 mg/dL over preceding 1 hTarget: 80--120 mg/dLTrigger: One blood glucose \> 130 or two blood glucoses \> 120 when checked 30 min apart. Bolus doses should not be necessary using this protocolHypoglycemia protocol (If blood glucose \< 70 mg/dL): Hold infusion, give 25 ml of 50% dextrose IV bolus (1/2 vial) and start 50mls/hr. 10% glucose. Re-check BG every 15 min until BG \> 70 mg/dL, then every 30 min

Hypoglycemia was defined as a single BG \< 70 mg/dL and was treated with 15 g of 50% dextrose. BG was evaluated to assess the response to treatment every 15 min until BG \> 70 mg/dL.

Outcomes {#Sec5}
--------

The primary outcomes were patient and graft survival at 1 year. Graft survival is defined by the United Network for Organ Sharing ([www.unos.org](http://www.unos.org)) as death or needing re-transplant. Secondary outcomes included patient and graft survival at 3 and 5 years, hospital length of stay, biliary and infectious complications (30 days), cardiac, thromboembolic complications, renal failure needing dialysis, re-operation and wound dehiscence at one year.

Statistical analysis {#Sec6}
--------------------

Basic descriptive statistics were calculated for demographics. Normality of continuous measures was assessed using Kolmogorov-Smirnov test. Pearson Chi-square or Fisher exact tests (for categorical variables) and independent two-tailed t-tests or Mann-Whitney U tests (for continuous variables) were used to assess baseline univariate clinical differences between patients who received strict glucose control and those who received conventional treatment. Survival and graft survival were analyzed using Kaplan Meier curves, with the log rank test for significance on an intention to treat basis.

Analysis was performed using SAS version 9.4 (SAS Institute, Cary, NC) and SPSS version 21.0 (IBM, Somers, NY). Computer-generated randomization was performed using STATA statistical software (StataCorp LP, College Station, Texas). A *p*-value of 0.05 was considered statistically significant.

A sensitivity analysis was performed to compare patients with a mean BG of ≤120 mg/dL and those \> 120 mg/dL regardless of randomized group. This cutoff was chosen based on treatment threshold for the strict control group.

Power analysis {#Sec7}
--------------

Based on published data \[[@CR2]\] the 1-year mortalities for the conventional and strict arms are predicted to be 22 and 9% respectively. A sample size of 89 has a greater than 80% power to detect a statistical difference between groups at the *p* = 0.05 level. A block randomization for diabetic and non-diabetic patients was used to ensure equal distribution of such patients between the treatment groups.

Results {#Sec8}
=======

Study populations and demographic characteristics {#Sec9}
-------------------------------------------------

Of the 175 patients screened, 105 patients were consented (two transplants were cancelled before enrollment, two patients were consented but not enrolled at transplant, one patient died during transplantation) and 100 patients completed the study; 50 were randomized to the conventional group and 50 were randomized to the strict glucose control group (Fig. [1](#Fig1){ref-type="fig"}). All patients were included for analysis and no patients were lost to follow up. There were no demographic or comorbidity differences between groups (Table [3](#Tab3){ref-type="table"}). Differences in transplant characteristics and surgical factors were not demonstrable between groups (Table [4](#Tab4){ref-type="table"}). Fig. 1Consort flow diagram Table 3Population and Baseline CharacteristicsCurrent Standard of Care (*N* = 50)Strict Glucose Control (*N* = 50)P-ValuePatient DemographicsAge55.0 \[50.0 to 59.0\]54.0 \[48.0 to 57.0\]0.201*Race*0.580 White41 (82.0)41 (82.0) African American4 (8.0)5 (10.0) Asian1 (2.0)0 (0.0) Other4 (8.0)4 (8.0)*WHO BMI Classification*0.415 Underweight0 (0.0)0 (0.0) Normal12 (24.5)10 (20.0) Overweight18 (36.7)14 (28.0)Obese19 (38.8)26 (52.0) Female Sex14 (28.0)12 (24.0)0.648Pre-Existing Conditions Diabetes16 (32.0)13 (26.0)0.509 CAD4 (8.0)4 (8.0)0.999 MELD Score20.5 \[15.0 to 23.0\]19.5 \[12.5 to 25.5\]0.744*Cause of Liver Disease*^*1*^ Alagille's Syndrome0 (0.0)2 (4.0)0.495 Alpha-1 Antitrypsin Deficiency4 (8.0)0 (0.0)0.118 Hepatocellular Carcinoma (non-Fibrolamellar)13 (26.0)19 (38.0)0.198 Alcohol-related Cirrhosis18 (36.0)12 (24.0)0.190 Cryptogenic Cirrhosis4 (8.0)5 (10.0)0.999 Primary Biliary Cirrhosis2 (4.0)1 (2.0)0.999 Secondary Biliary Cirrhosis1 (2.0)0 (0.0)0.999 Cystic Fibrosis1 (2.0)0 (0.0)0.999 Hemochromatosis1 (2.0)0 (0.0)0.999 Hepatitis C, Chronic18 (36.0)18 (36.0)0.999 Hepatitis, Chronic Active2 (4.0)3 (6.0)0.999 Hepatic Failure (Idiopathic)1 (2.0)0 (0.0)0.999 HCC1 (2.0)1 (2.0)0.999 Hypertensive Nephrosclerosis1 (2.0)0 (0.0)0.999 Polycystic Liver Disease1 (2.0)0 (0.0)0.999 Non-Alcoholic Steatohepatitis2 (4.0)4 (8.0)0.678 Primary Sclerosing Cholangitis5 (10.0)8 (16.0)0.554 Unknown1 (2.0)1 (2.0)0.999 Wilson's Disease0 (0.0)1 (2.0)0.999^1^Cause of liver disease is not mutually exclusive. Data are presented as frequency (%) or median \[25th percentile to 75th percentile\], as appropriate Table 4Transplant characteristics, surgical factors, and post-surgical complicationsCurrent standard of care (*N* = 50)Strict glucose control (*N* = 50)P-ValueTransplant Characteristics and Surgical Factors High Risk Donor5 (10.0)7 (14.0)0.538 Warm Ischemic Time (Minutes)26.0 \[23.0 to 32.0\]27.0 \[23.0 to 33.0\]0.916 Cold Ischemic Time (Minutes)400.0 \[323.0 to 488.0\]385.5 \[333.0 to 429.0\]0.572 Total Ischemic Time (Minutes)431.0 \[354.0 to 522.0\]415.5 \[367.0 to 455.0\]0.575 Total Surgical Time (Minutes)313.0 \[281.0 to 369.0\]329.9 \[307.0 to 375.8\]0.228Intraoperative Blood Product Usage Packed red cells (mL)2450.0 \[1050.0 to 3850.0\]2450.0 \[1400.0 to 3500.0\]0.475 Platelets (mL)500.0 \[500.0 to 750.0\]625.0 \[375.0 to 750.0\]0.667 Cryoprecipitate (mL)200.0 \[100.0 to 200.0\]200.0 \[100.0 to 400.0\]0.438 Cell Saver (mL)999.0 \[500.0 to 1425.0\]848.0 \[700.0 to 1600.0\]0.645Data are presented as frequency (%) or median \[25th percentile to 75th percentile\], as needed

Insulin dose, treatment response and hypoglycemia {#Sec10}
-------------------------------------------------

Within the conventional group the mean intraoperative BG was 143.3 mg/dL \[interquartile range (IQR) 123.8 mg/dL to 167.1 mg/dL\] and for the strict group 130.7 mg/dL \[IQR 112.2 mg/dL to 154.8 mg/dL\] (*p* = 0.020, Table [5](#Tab5){ref-type="table"}). Patients in the strict control group received more insulin (median: 24.4 units \[IQR 14.2 to 38.0\] vs. 10.0 units \[IQR 5.9 to 17.8\], *p* \< 0.001). Mean BG values over time showed statistically significant difference (*p* = 0.037) between the strict and standard control group with a divergent trajectory following reperfusion of donor graft (Fig. [2](#Fig2){ref-type="fig"}). Within the conventional group, seven patients were exposed to at least one hypoglycemic incident; six patients had one episode, one patient had two episodes. Within the strict glucose control group 13 patients exhibited one hypoglycemic episode. Table 5Glucose controlCurrent standard of care (*N* = 50)Strict glucose control (*N* = 50)P-ValueTotal No. of Hypoglycemia Incidents0.125 043 (86.0)37 (74.0) 16 (12.0)13 (26.0) 21 (2.0)0 (0.0)Hypoglycemia at any time7 (14.0)13 (26.0)0.134Total Insulin Dosage10.0 \[5.9 to 17.8\]24.4 \[14.2 to 38.0\]\< 0.001Mean Intraoperative Glucose143.3 \[123.8 to 167.1\]130.7 \[112.2 to 154.8\]0.020Data are presented as frequency (%) or median \[25th percentile to 75th percentile\], as needed Fig. 2Mean intraoperative blood glucose with 95% confidence intervals for standard and strict glycemic control groups. The vertical dashed line represents the median revascularization time, which was similar in both groups

Survival and graft loss {#Sec11}
-----------------------

The primary study (one-year survival) and secondary outcomes for graft and patient (three and five-year survival) are represented in Table [6](#Tab6){ref-type="table"}. Patient survival was not different between conventional and strict groups respectively, (1 year: 88% vs 88%, *p* = 0.999; 3 years: 86% vs 84%, *p* = 0.779; 5 years: 82% vs 78%, *p* = 0.617). There was no statistical difference in causes of mortality between the two groups (data not shown). Graft survival was not different between conventional and strict control groups respectively, (1 year: 88% vs 84%, *p* = 0.564; 3 years: 82% vs 76%, *p* = 0.461; 5 years: 78% vs 70%, *p* = 0.362). In-hospital graft survival was not statistically significant between treatment groups (*p* = 0.118). Kaplan-Meier 5-year survival rate not reveal any statistically significant difference between the two groups (*p* = 0.490, Fig. [3](#Fig3){ref-type="fig"}a). Fig. [3](#Fig3){ref-type="fig"}b shows the same trend for the 5-year graft survival rate (*p* = 0.303). There was no difference in postoperative ICU stay between groups (median: 3.0 days \[IQR 2.0 to 5.0 for both\]; *p* = 0.934). Table 6Post-surgical complicationsCurrent standard of care (*N* = 50)Strict glucose control (*N* = 50)P-ValueSurvival Outcomes Graft Loss11 (22.0)16 (32.0)0.260 Death9 (18.0)12 (24.0)0.461Overall Survival 30 Day Survival49 (98.0)49 (98.0)0.999 1 Year Survival44 (88.0)44 (88.0)0.999 3 Year Survival43 (86.0)42 (84.0)0.779 5 Year Survival41 (82.0)39 (78.0)0.617Graft Survival 30 Day Graft Survival48 (96.0)49 (98.0)0.999 1 Year Graft Survival44 (88.0)42 (84.0)0.564 3 Years Graft Survival41 (82.0)38 (76.0)0.461 5 Years Graft Survival39 (78.0)35 (70.0)0.362Complications Bile Leak15 (30.0)14 (28.0)0.826 Biliary Stricture20 (40.0)13 (26.0)0.137 CVA1 (2.0)0 (0.0)0.999 Hepatic Arterial Stricture3 (6.0)1 (2.0)0.617 Major Cardiac Event5 (10.0)4 (8.0)0.999 Portal Vein Thrombosis3 (6.0)3 (6.0)0.999 Re-operation: Bleeding6 (12.0)10 (20.0)0.275 Re-operation: Other9 (18.0)15 (30.0)0.160 Renal Failure - Dialysis9 (18.0)6 (12.0)0.401 Wound Dehiscence5 (10.0)12 (24.0)0.062Infections Bacterial26 (52.0)27 (54.0)0.841 Fungal7 (14.0)11 (22.0)0.298 Transplant Incision Wound7 (14.0)9 (18.0)0.585 Viral6 (12.0)4 (8.0)0.505Hospital Outcomes Length of Stay (days)11.0 \[8.0 to 19.0\]12.5 \[8.0 to 19.0\]0.384Data are presented as frequency (%) or median \[25th percentile to 75th percentile\], as needed Fig. 3Overall survival for standard and strict glycemic control groups with time along the X-axis and survival probability along the Y-axis. A) Five-year mortality, log- rank test *p* = 0.490. B) Five-year graft survival log-rank test *p* = 0.303

Biliary, infectious and other complications {#Sec12}
-------------------------------------------

Despite some clinically significant differences between the treatment groups, there were no statistically significant differences between the strict and conventional group for any secondary outcome measures which included bile leak (*p* = 0.826), re-operation for bleeding (*p* = 0.275), renal failure needing dialysis (*p* = 0.401), bacterial infection (*p* = 0.841), fungal infection (*p* = 0.298), wound infection (*p* = 0.585) and viral infection (*p* = 0.505) (Table [6](#Tab6){ref-type="table"}).

Sensitivity analysis {#Sec13}
--------------------

A sensitivity analysis was performed to compare patients with a mean BG of ≤120 mg/dL and those \> 120 mg/dL, regardless of treatment group, to assess the response to insulin treatment or insulin resistance. The sensitivity analysis included all 100 patients; of those with BG \< 120 mg/dL, 19 (70.4%) were from the strict control group and 8 (29.6%) were from the conventional group. There was statistically significant improved survival for patients with a mean intraoperative BG of ≤120 mg/dL with a log rank *p* value of 0.047 (Fig. [4](#Fig4){ref-type="fig"}). Fig. 4Overall 5-year patient survival comparing patients with mean blood glucose less than or equal to 120 mg/dL to those with a mean blood glucose greater than 120 mg/dL with time along X-axis and survival probability along Y-axis. The log-rank test *p* = 0.047

After adjustment for patient comorbidities, chronic preoperative steroid use, and intraoperative transfusion using a multivariable Cox proportional hazard model, blood glucose ≤120 mg/dL did not show any significant difference in survival.

Discussion {#Sec14}
==========

We report the first randomized study directly comparing strict versus conventional glucose control during the intraoperative period of liver transplantation with comprehensive long term follow up. We found no difference in patient or graft survival after OLT between the conventional and strict glucose control regimens when analyzed on an intention to treat basis. However, the sensitivity analysis revealed improved survival for those patients with a mean blood glucose ≤120 mg/dL regardless of treatment group, perhaps identifying a group of 'responders' or implying the requirement for more aggressive insulin management than that used within our strict control group.

Although patients in the strict group received greater than twice the dose of insulin and exhibited an approximate 10% reduction in mean intraoperative blood glucose when compared to the conventional group; these differences may not have been large enough to produce a clinically significant difference in the outcomes measured. However, most divergence in blood glucose between groups can be appreciated only after reperfusion perhaps illustrating that reliance on differences in the mean of the total operative time to be limited. The strict glucose regimen was modified from the landmark NICE-SUGAR trial, \[[@CR12]\] the most aggressive regimen published to date, and associated with a 7% incidence of severe hypoglycemia (\< 40 mg/dL). Within the conventional group, 7 patients were exposed to at least one hypoglycemic incident; 6 patients had one episode, 1 patient had two episodes. Within the strict glucose control group 13 patients exhibited 1 hypoglycemic episode. Numerically, hypoglycemic episodes were higher in the strict control group although there was no statistically significant difference between the number of patients exposed to hypoglycemia or the total number of hypoglycemic episodes between groups. The routine provision of abundant anesthesia resources for liver transplantation allowed for frequent glucose monitoring and rapid intervention for changes in plasma glucose when detected and may enhance safety for aggressive glucose management in this patient population. Patients undergoing liver transplant have the potential to exhibit hyperglycemia due to insulin resistance \[[@CR9]\] and the exogenous administration of steroids may make hypoglycemia less likely; it appears that aggressive insulin therapy is not associated with a greater risk of hypoglycemia compared to conventional control and can be managed safely during the intraoperative phase of liver transplantation.

We found a statistically significant difference in patient survival if mean BG was less than 120 mg/dl in the sensitivity analysis although the adjusted analysis did not show any significant difference A recent prospective study investigated postoperative glycemic control and impact on outcomes at one year following liver transplantation and revealed a reduced incidence of infection with BG levels of 140 mg/dl but a higher incidence of moderate hypoglycemia (41--70 mg/dl) was described \[[@CR13]\]. We did not continue randomization into the postoperative period but doing so as well as monitoring all elements of glucose control throughout the first postoperative year are likely of critical importance for the outcomes measured and represent a design flaw within this study.

Hyperglycemia is associated with a spectrum of poor outcomes including poor graft survival \[[@CR14]\] and in animal studies is associated with defective handling of calcium in cardiac myocytes resulting in poor cardiac function \[[@CR15]\]. Insulin treatment appears to reduce afterload and improve ventricular relaxation although changes in myocardial perfusion or contractility have not been demonstrated \[[@CR16]\]. Treatment of hyperglycemia, especially in patients with non-insulin dependent DM, has been shown to improve immune function, hypercoagulability and possibly reduce the risk of infectious complications \[[@CR1]\]; it is postulated that hyperglycemia results in impaired phagocytosis secondary to high intra-cellular calcium concentrations. In addition to hepatgeneous diabetes, immunosuppression with steroids and stress hyperglycemia likely contribute to profound fluctuations in BG levels during liver transplantation \[[@CR8], [@CR17], [@CR18]\]. It is interesting to note that we found no differences in infectious complications between groups here. The precise mechanism of stress induced hyperglycemia is not clear but it is associated with poor post-operative outcomes following non-cardiac surgery \[[@CR19]\]. Insulin resistance is likely a primary factor and general anesthesia per se may be contributory; a recent animal study reveals an increase in insulin resistance by almost 50% and insulin effects at the liver were almost completely suppressed \[[@CR20]\]. Liver transplantation is associated with potential for significant blood loss and transfusion. Citrate phosphate dextrose (CPD) preservative solutions contribute to serum glucose; there was no difference in transfusion requirements between treatment groups.

Despite decades of research conducted within the intensive care setting glucose control remains controversial and strict control is currently not recommended for critically ill patients \[[@CR21]\]. The thresholds to treat hyperglycemia in the cardiac surgical population may be lower compared to non-cardiac surgical patients potentially related to the effects of metabolic syndrome and hyperglycemia during cardiopulmonary bypass \[[@CR22]\]. It is possible that patients undergoing liver transplantation share similarity with cardiac surgical patients as signaled by the results of our sensitivity analysis. There is a lack of robust data from the perioperative setting in the non-cardiac surgical patients. Our current practice is mostly based upon retrospective investigations which suggests BG \> 200 mg/dL is associated with poor outcomes \[[@CR23], [@CR24]\]. Any improved outcome implied from our sensitivity analysis may not only impact OLT but may be of broader significance for other non-cardiac surgical patients as there is lack of good evidence in defining treatment strategies As implied by our data, it is possible to implement tight control safely with careful monitoring of BG during the intraoperative phase of an OLT \[[@CR25]\]. Outcome differences in perioperative glycemic control may not be solely related to glycemic control per se, but may also be attributed to differences in the level of supervision, accuracy of monitoring, clinical setting and infusion practices \[[@CR26]\].

Previous studies have reported that glucose variability was associated with acute kidney injury following OLT \[[@CR24], [@CR27], [@CR28]\] which was not related directly to hyperglycemia or hypoglycemia. However, this study did not detect a difference in the requirement for dialysis post-operatively between groups but we did not measure glucose variability. In terms of detecting glucose variability, technological advances for continuous glucose monitoring and real time alerting systems may be helpful in achieving stability of BG \[[@CR29], [@CR30]\]. Intravenous insulin infusions have advantage over \[[@CR31]\] subcutaneous bolus or the widely used sliding scale in maintaining steady state to prevent glucose variability \[[@CR32]--[@CR34]\].

There are limitations with our study. The sample size was small and the study population was heterogeneous. We did not achieve the target BG in the strict group, despite the use of an aggressive insulin protocol, potentially related to insulin resistance seen in patients with liver disease and the measurable difference in BG between groups may have been of insufficient magnitude to result in a meaningful clinical difference between groups. Although current evidence does not recommend strict control in the perioperative period, our strict control group was defined based on the existing literature at the time of study initiation. However, the statistically significant difference in the intraoperative BG level between groups diverged as the case progressed. The study focused exclusively on intraoperative glycemic control; including the immediate postoperative phase would have been a major improvement in study design. However, differences in patient survival following liver transplant are associated with intraoperative BG control \[[@CR10]\] and a large retrospective study in non-cardiac surgery found that a higher mean intraoperative BG increased the odds for higher post-operative BG, \[[@CR35]\] implying that control of the intraoperative phase of care is a rational research question. In addition, poor glycemic control in the intraoperative period adversely impacts outcome \[[@CR5], [@CR36], [@CR37]\] yet the influence of postoperative management cannot be underestimated \[[@CR35]\]. Lastly, we did not evaluate glucose homeostasis in donors but improved recipient outcome has been achieved with improved glycemic control in donors \[[@CR38]\]. A direct relationship between donor and recipient glucose variability may exist and be an unmeasured confounder within this study.

Conclusion {#Sec15}
==========

In conclusion, there is no patient or graft survival advantage with strict glucose management compared to conventional glucose management during the intraoperative phase for patients undergoing liver transplantation when evaluated on an intention to treat basis.

BG

:   Blood glucose

OLT

:   Orthotopic liver transplant
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